- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Monkeypox virus
- Pharmacological intervention
- Antivirals
- Tecovirimat
Population: Adolescents (12-17 years)
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- Community
- Non-hospital health centre
- SARS-CoV-2
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- General population
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- Monkeypox virus
- General population
- Children (1-11 years)
- Adolescents (12-17 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- General population
- Children (1-11 years)
- Adolescents (12-17 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- General population
- Adolescents (12-17 years)
- Non-hospital health centre
- Telemedicine
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- Monkeypox virus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Children (1-11 years)
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Adolescents (12-17 years)
- Immunocompromised host
- Outpatient clinic
- Community
- Non-hospital health centre
- SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation